The 340B spread mechanism permits covered entities to retain the difference between discounted acquisition cost and commercial or Medicare reimbursement, incentivizing revenue capture rather than ...

Exclusive ex-China rights extend to up to 10 partnered biosimilar programs, positioning Sandoz to shape development and registration strategy using early commercial and market-access input. Financial ...

Rohit Tripathi, VP of Industry Strategy at RELEX, discusses how pharmaceutical reshoring demands end-to-end capability not ...

Pharmaceutical Executive releases its 2026 Top 50 company rankings, FDA grants Bristol Myers Squibb's Zenbexus accelerated ...

Capital continues to flow toward clinical-stage and platform biotech companies, with a wave of new deals, partnerships, and ...

Lewis W. Coopersmith is an associate professor at Rider University and vice-president of Health Products Research.

A funding roundup covers new IPO and Series A raises across Silence Therapeutics, AbCellera, Beyang Therapeutics, and Remepy, Tyler Seville of ADVI examines the policy concerns building around the ...

FDA authorization covers adults ≥50, positioning mFLUSIVA as Moderna’s first mRNA influenza vaccine and expanding its US ...

Accelerated approval allows iberdomide with daratumumab/hyaluronidase and dexamethasone for adults with RRMM after ≥1 line including a proteasome inhibitor and an ...

In July of this year, Krieger Scientific issued a release addressing the increase in 303 drug warning letters issued by FDA. In 2025, as new leadership took over the agency, FDA sent 303 drug warning ...

Last week, reports emerged of a potential merger between AstraZeneca and Bristol Myers Squibb. While a senior source reportedly debunked these rumors days later, the news caused an uproar across the ...

Reauthorization of the PRV program provides multi-year policy certainty and a monetizable voucher that can deliver significant non-dilutive funding upon sale. Absent a PRV-like mechanism, UK ...